ClinicalTrials.gg
CompletedNCT03101163Updated Aug 16, 2022

Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee

A Phase 2 interventional study of Autologous peripheral blood stem cells and hyaluronic acid and Hyaluronic acid in Articular Cartilage Disorder of Knee and Articular Cartilage; Degeneration, sponsored by KLSMC Stem Cells, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by KLSMC Stem Cells, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 4 months ago, and no results have been posted to the registry.
  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2015, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, Phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. The safety and efficacy of intra-articular injections of peripheral blood stem cells (PBSCs) together with hyaluronic acid (HA) after subchondral drilling surgery will be evaluated to determine whether PBSC therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (HA injections and physiotherapy regimen).

Read the detailed description

This is a 24-month, multicenter, randomized, open-label, standard treatment-controlled, parallel-group, Phase 2 study for adults with large or complicated knee articular cartilage lesions and are candidates for knee joint cartilage repair surgery. The safety and efficacy of intra-articular injections of peripheral blood stem cells (PBSCs) together with hyaluronic acid (HA) after subchondral drilling surgery will be evaluated to determine whether PBSC therapy can improve functional outcome and reduce pain of the knee joint better than a standard treatment (HA injections and physiotherapy regimen).

02

Conditions studied

  • Articular Cartilage Disorder of Knee
  • Articular Cartilage; Degeneration
03

In context

Lead sponsor

This is the only study on the registry with KLSMC Stem Cells, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 to 55 years at screening (20 to 57 years for the open-label extension)
  • Present for evaluation and treatment of knee pain, knee swelling, or knee mechanical symptoms due to cartilage lesions
  • Provide written
  • International Cartilage Repair Society (ICRS) Grade 3 or 4 lesions diagnosis from MRI scans of the target knee
  • All subjects must also satisfy at least 1 of the following inclusion criteria:

    • Isolated knee articular cartilage lesion (single lesion) estimated to be ≥3 cm2 as demonstrated on MRI scanning. Multiple knee articular cartilage lesions (multiple lesions) with at least 1 lesion estimated to be ≥3 cm2 as demonstrated on MRI scanning. Bipolar cartilage defects demonstrated on MRI scanning with at least 1 articular surface lesion to be ≥3 cm2. One or more cartilage defects involving the patello-femoral joint as demonstrated on MRI scanning with at least 1 lesion ≥3 cm2. One or more cartilage defects involving the tibio-femoral joint as demonstrated on MRI scanning with at least 1 lesion to be ≥3 cm2. Previously failed cartilage repair procedures (i.e., microfracture, osteochondral autograft transplantation surgery (OATS), ACI)

Exclusion criteria

Exclusion Criteria:

  • Three or more previous surgical interventions on the knee in question.
  • Preoperative flexion deformity greater than 10 degrees.
  • Presence of ligamentous injury which would require reconstruction, varus or valgus deformity requiring osteotomy, or cases that require complex surgery prior to cartilage regeneration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention

    Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.

    Biological: Autologous peripheral blood stem cells and hyaluronic acid

  • Active comparator
    Standard treatment

    Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.

    Other: Hyaluronic acid

Interventions

  • BiologicalAutologous peripheral blood stem cells and hyaluronic acid

    Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy

  • OtherHyaluronic acid

    Regimen of intra-articular HA injections and postoperative physiotherapy

06

What researchers measure

Primary outcomes

  1. International Knee Documentation Committee (IKDC) score

    Subjective IKDC core as a measure of joint function

    Time frame: 24 months

  2. Knee injury and Osteoarthritis Outcome (KOOS) pain subdomain

    KOOS pain subdomain score as a measure of joint pain

    Time frame: 24 months

Secondary outcomes

  1. Numeric Rating Scale (NRS) for pain

    Numeric Rating Scale (NRS) for pain

    Time frame: 24 months

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: up to 24 months

07

Study locations

2 sites
  • Andrews Research & Education Foundation (AREF)
    Gulf Breeze, Florida 32561, United States
  • Kuala Lumpur Sports Medicine Centre
    Kuala Lumpur, Malaysia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Jul 2022, 79 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2017
First posted
Apr 4, 2017
StartActual
Dec 2015
Primary completionActual
Jul 2022
CompletionActual
Jul 2022
Last update
Aug 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03101163
Lead sponsor
KLSMC Stem Cells, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Dec 2015
Primary completion
Jul 2022
Completion
Jul 2022
Last update
Aug 16, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion